Literature DB >> 19770659

Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.

Elena Csernok1, Peter Lamprecht, Wolfgang L Gross.   

Abstract

PURPOSE OF REVIEW: Drugs and infections may induce antineutrophil cytoplasmic antibodies (ANCA) and vasculitic manifestations mimicking ANCA-associated vasculitides (AAV) and mechanisms relevant in their pathogenesis. This review summarizes the most recent findings in this field. RECENT
FINDINGS: Drug-induced and infection-induced proteinase 3 (PR3)-ANCA and myeloperoxidase (MPO)-ANCA may be associated with a vasculitis clinically resembling AAV. Mechanisms relevant for the break of tolerance and induction of ANCA (e.g. danger signals, superantigens, neutrophil extracellular traps, protease-activated receptor-2, IL-17 cells) may be shared to some extent between drug-induced and infection-induced ANCA-positive vasculitis and AAV, especially with regard to the potential role of infection in Wegener's granulomatosis. Differences in immunopathology, clinical presentation, and functional aspects of ANCA help to distinguish drug-induced and infection-induced ANCA-positive vasculitis from AAV, and present new avenues for future research in this field.
SUMMARY: Medications and infections, which induce PR3-ANCA and MPO-ANCA, have to be considered in the differential diagnosis of primary AAV. Moreover, there is clinical and experimental evidence for an association between certain drugs and infections with ANCA-production. Analysis of ANCA-induction in such conditions also sheds new light on our understanding of immune mechanisms relevant in the break of tolerance and ANCA-production in AAV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19770659     DOI: 10.1097/BOR.0b013e3283323538

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  16 in total

Review 1.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

2.  [Secondary vasculitides and vasculitis mimics].

Authors:  K de Groot; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

3.  Pyrexia of unknown origin and pulmonary fibrosis as a presentation of MPO-ANCA associated vasculitis.

Authors:  O Shields; A Shah; B Mann
Journal:  BMJ Case Rep       Date:  2011-04-15

Review 4.  Granuloma in ANCA-associated vasculitides: another reason to distinguish between syndromes?

Authors:  Antje Mueller; Konstanze Holl-Ulrich; Wolfgang L Gross
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

5.  Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge.

Authors:  Branka Bonaci-Nikolic; Sladjana Andrejevic; Milorad Pavlovic; Zoran Dimcic; Branislava Ivanovic; Milos Nikolic
Journal:  Clin Rheumatol       Date:  2010-03-20       Impact factor: 2.980

6.  Complements do not lie.

Authors:  Stefanie Christina Robert; Suzanne Helen Forbes; Surusch Soleimanian; Julia S Hadley
Journal:  BMJ Case Rep       Date:  2011-12-01

Review 7.  ANCA-associated vasculitis with renal involvement.

Authors:  Valentina Binda; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-30       Impact factor: 3.902

8.  Unusual extracardiac manifestations of isolated native tricuspid valve endocarditis.

Authors:  M Wilczynska; J P Khoo; G P McCann
Journal:  BMJ Case Rep       Date:  2010-11-29

9.  Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA-associated vasculitis.

Authors:  Henko Tadema; Wayel H Abdulahad; Coen A Stegeman; Cees G M Kallenberg; Peter Heeringa
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

Review 10.  Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides.

Authors:  Julia U Holle; Frank Moosig; Klaus Dalhoff; Wolfgang L Gross
Journal:  Arthritis Res Ther       Date:  2011-06-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.